Delving into the Latest Updates on Hunan Mingrui Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Infectious Diseases

Digestive System Disorders

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	2

Top 5 Drug Type	Count

Small molecule drug	2

本试验旨在研究单次餐后口服湖南明瑞制药有限公司研制、生产的马来酸阿伐曲泊帕片（20 mg）的药代动力学特征；以AkaRx Inc.持证、Kawashima Plant, Eisai Co.,Ltd.生产的马来酸阿伐曲泊帕片（苏可欣®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性，并观察两制剂在健康受试者中的安全性。

[Translation]

This study aims to study the pharmacokinetic characteristics of avatrombopag maleate tablets (20 mg) developed and produced by Hunan Mingrui Pharmaceutical Co., Ltd. after a single oral administration after meal; using avatrombopag maleate tablets (Sukoxin®, 20 mg) certified by AkaRx Inc. and produced by Kawashima Plant, Eisai Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, evaluate the human bioequivalence of the two preparations, and observe the safety of the two preparations in healthy subjects.

Start Date20 Sep 2022

Sponsor / Collaborator

Hunan Mingrui Pharmaceutical Co. Ltd.

CTR20221737 / CompletedNot Applicable

马来酸阿伐曲泊帕片人体生物等效性研究（空腹试验）

[Translation] Bioequivalence study of avatrombopag maleate tablets in humans (fasting test)

本试验旨在研究单次空腹口服湖南明瑞制药有限公司研制、生产的马来酸阿伐曲泊帕片（20 mg）的药代动力学特征；以AkaRx Inc.持证、Kawashima Plant, Eisai Co.,Ltd.生产的马来酸阿伐曲泊帕片（苏可欣®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性，并观察两制剂在健康受试者中的安全性。

[Translation]

This study aims to study the pharmacokinetic characteristics of a single fasting oral dose of avatrombopag maleate tablets (20 mg) developed and produced by Hunan Mingrui Pharmaceutical Co., Ltd.; using avatrombopag maleate tablets (Sukoxin®, 20 mg) certified by AkaRx Inc. and produced by Kawashima Plant, Eisai Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, evaluate the human bioequivalence of the two preparations, and observe the safety of the two preparations in healthy subjects.

Start Date13 Sep 2022

Sponsor / Collaborator

Hunan Mingrui Pharmaceutical Co. Ltd.

CTR20210698 / RecruitingNot Applicable

草木犀流浸液片人体药代动力学研究

[Translation] Study on the pharmacokinetics of Melilotifolia infusion tablets in healthy volunteers

本试验旨在研究单次空腹口服湖南明瑞制药有限公司研制、生产的草木犀流浸液片〔400 mg（含草木犀流浸液25 mg）〕的药代动力学特征；以生晃荣养药品株式会社生产的草木犀流浸液片〔消脱止-M®，400 mg（含草木犀流浸液25 mg）〕为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞。

[Translation]

The purpose of this study was to study the pharmacokinetic characteristics of a single oral fasting dose of Mesorhizium oxyphylla fluid infusion tablets (400 mg (containing Mesorhizium oxyphylla fluid infusion 25 mg)) developed and produced by Hunan Mingrui Pharmaceutical Co., Ltd.; using Mesorhizium oxyphylla fluid infusion tablets (Xiaoduozhi-M®, 400 mg (containing Mesorhizium oxyphylla fluid infusion 25 mg)) produced by Shenghuang Rongyang Pharmaceutical Co., Ltd. as the reference preparation, and to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations.

Start Date02 Apr 2021

Sponsor / Collaborator

Hunan Mingrui Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hunan Mingrui Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Hunan Mingrui Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Hunan Mingrui Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Hunan Mingrui Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Methenamine Hippurate	Lower Urinary Tract Symptoms More	Approved
Glycyrrhizin	Chronic liver disease More	Approved
Rabeprazole Sodium ( Proton pump )	gastric ulcer benign More	Pending